Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07065968 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

Name: The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2) — clinical trial record (NCT07065968)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorPeking University People's Hospital

Started2025-08-19

View on ClinicalTrials.gov ↗

Amendment history

2025-08-31

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-07-15→confirmed 2025-08-19

Study sitesdetails revised at 3 of 3 sites

2025-07-04

Original filing

Peking University People's Hospital

220 trials monitored

See 6 trials at risk

A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).

Trial Details

NCT Number	NCT07065968
Lead Sponsor	Peking University People's Hospital Collaborators: Peking University Health Science Center, Cisen Pharmaceutical CO., LTD.
Conditions	Immune Thrombocytopenia (ITP)
Enrollment	132 participants
Start Date	2025-08-19
Primary Completion	2027-09-10 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-08